|
|
News
Press Releases
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial
06-18-09
|
12.0 KB
|
| |
ANN ARBOR, Mich., June 18, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today reported that the U.S. Food and Drug Administration (FDA) has removed the clinical hold from the Company's U.S. Phase II IMPACT-DCM clinical trial...
|
|
|
Aastrom Proactively Places Phase II IMPACT-DCM Clinical Trial On Hold Following Report of Serious Adverse Event
05-22-09
|
10.3 KB
|
| |
ANN ARBOR, Mich., May 22, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that the Company has temporarily suspended enrollment and patient treatment in its U.S. Phase II IMPACT-DCM clinical trial following a re...
|
|
|
Aastrom Reports Third Quarter Fiscal Year 2009 Financial Results
05-08-09
|
16.7 KB
|
| |
ANN ARBOR, Mich., May 8, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today reported financial results for the third fiscal quarter ended March 31, 2009. The Company also reviewed several clinical and operational achievement...
|
|
|
Initial Data From Aastrom's IMPACT-DCM Trial Presented At International Society for Cellular Therapy Annual Meeting by Amit N. Patel, M.D.
05-05-09
|
12.4 KB
|
| |
ANN ARBOR, Mich., May 5, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced today that Dr. Amit N. Patel, Associate Professor of Surgery at the University of Utah School of Medicine and the National Principal Investigato...
|
|
|
Aastrom Biosciences Receives Notification That NASDAQ Further Extends Suspension of Certain Continued Listing Requirements
03-23-09
|
8.3 KB
|
| |
ANN ARBOR, Mich., March 23, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced that the Company received Issuer Alert #2009-002 from The Nasdaq Stock Market LLC ("NASDAQ"). The Issuer Alert states that, given the continu...
|
|
|
Aastrom Commends Expansion of Federal Support for Stem Cell Research
03-10-09
|
9.6 KB
|
| |
ANN ARBOR, Mich., March 10, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today commended the expansion of federal support designed to advance stem cell research. The Company is particularly pleased to note the willingness of...
|
|
|
FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial
03-03-09
|
10.7 KB
|
| |
ANN ARBOR, Mich., March 3, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported that the U.S. Food and Drug Administration (FDA) has removed the clinical hold from the Company's U.S. Phase II IMPACT-DCM clinical trial and that patient enrollment would resume at the four initiated ...
|
|
|
Aastrom Reports Second Quarter Fiscal Year 2009 Financial Results
02-06-09
|
16.1 KB
|
| |
ANN ARBOR, Mich., Feb. 6, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for its second fiscal quarter ended December 31, 2008. The Company also reported several clinical and operational achievements since the beginning of the second fiscal quarter, includi...
|
|
|
Aastrom Biosciences to Present At the 11th Annual BIO CEO & Investor Conference
02-04-09
|
8.3 KB
|
| |
ANN ARBOR, Mich., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George W. Dunbar, President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference. The conference will be held February 9-10th at the Waldorf-Astoria Hotel in ...
|
|
|
Aastrom Phase II IMPACT-DCM Clinical Trial Placed On Clinical Hold Pending Review of Isolated Serious Adverse Event Related to Anesthesia Management in One Patient
02-02-09
|
10.9 KB
|
| |
ANN ARBOR, Mich., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported that one patient enrolled in the Company's U.S. Phase II IMPACT-DCM clinical trial experienced a serious adverse event associated with anesthesia management during treatment at one of the active clinica...
|
|
|
Aastrom Announces Treatment of First Patient in U.S. Phase II IMPACT-DCM Trial
11-20-08
|
11.4 KB
|
| |
ANN ARBOR, Mich., Nov. 20, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the first patient has been treated in its randomized, controlled, prospective, open-label IMPACT-DCM clinical trial. Currently enrolling patients at The Methodist Hospital in Houston, TX, Baylor ...
|
|
|
Aastrom Biosciences Reports First Quarter Fiscal Year 2009 Financial Results
11-07-08
|
15.8 KB
|
| |
ANN ARBOR, Mich., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the first fiscal quarter ended September 30, 2008. The Company also reported several recent clinical and operational achievements, including:
* U.S. Phase II cardiac regene...
|
|
|
Aastrom Biosciences to Present At Rodman & Renshaw 10th Annual Healthcare Conference
11-07-08
|
9.2 KB
|
| |
ANN ARBOR, Mich., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Martin C. Peters, PhD, Senior Director, Business Strategy & Market Development, will present at the Rodman & Renshaw 10th Annual Healthcare Conference. The conference will be held November 10-12th...
|
|
|
Aastrom Announces Achievement of Milestone in U.S. Phase IIb Critical Limb Ischemia Clinical Trial
10-30-08
|
10.2 KB
|
| |
ANN ARBOR, Mich., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the 30th patient has been treated in the Company's U.S. Phase IIb RESTORE-CLI clinical trial. This milestone marks the first step toward interim data retrieval from this clinical trial evaluating...
|
|
|
Aastrom Biosciences Receives Notification That NASDAQ Issued Temporary Suspension of Certain Continued Listing Requirements
10-28-08
|
9.2 KB
|
| |
ANN ARBOR, Mich., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, announced that the Company received notification from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("NASDAQ") that, given the current extraordinary market conditions, NASDAQ had suspended enf...
|
|
|
Aastrom Biosciences, Inc. Proxy Proposals Approved
10-27-08
|
10.8 KB
|
| |
ANN ARBOR, Mich., Oct. 27, 2008 (GLOBE NEWSWIRE) -- Aastrom
Biosciences, Inc. (NasdaqCM:ASTM - News), a leading regenerative
medicine company, today announced that shareholders of the
Company approved all fiscal year 2008 proxy proposals at
the ...
|
|
|
Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders
10-13-08
|
8.7 KB
|
| |
ANN ARBOR, Mich., Oct. 13, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences (Nasdaq:ASTM) announces the following Webcast:
What: Aastrom Biosciences Fiscal Year 2008 Annual Meeting of
Shareholders
When: Friday, October 17, 2008 @ 9:00 am (Eastern)
Where: http://www.investorcalendar.com/IC/CEPage.asp?ID=134463
How: ...
|
|
|
Institutional Shareholder Services, Inc. Recommends Aastrom Shareholders Vote 'FOR' Fiscal Year 2008 Good Corporate Governance Proxy Proposals
09-29-08
|
10.3 KB
|
| |
ANN ARBOR, Mich., Sept. 29, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Institutional Shareholder Services, Inc. (ISS), a wholly-owned subsidiary of RiskMetrics Group, Inc., one of the nation's leading proxy advisory firms, has recommended that Aastrom shareholders ...
|
|
|
Aastrom Biosciences, Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results
08-29-08
|
20.4 KB
|
| |
ANN ARBOR, Mich., Aug 29, 2008 (GlobeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the fourth quarter and fiscal year ended June 30, 2008. The Company also reported clinical and operational achievements during the quarter, including:
...
|
|
|
Webcast Alert: Aastrom Announces Fourth Quarter Investor Conference Call
08-26-08
|
9.4 KB
|
| |
ANN ARBOR, Mich., Aug 26, 2008 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) announces the following Webcast:
What: Aastrom Biosciences, Inc. 4th Quarter Fiscal Year 2008 Investor Conference Call
When: Friday, August 29, 2008 @ 11:00 am (EDT)
Where: http://www.investorcalendar.com/IC/CEPage.asp?ID=133137
How: aEURc For ...
|
|
|
|
Shareholder Tools
|
Print page |
Email page
